R
Roxana Rustomjee
Researcher at National Institutes of Health
Publications - 53
Citations - 5750
Roxana Rustomjee is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Tuberculosis & Population. The author has an hindex of 23, co-authored 50 publications receiving 5138 citations. Previous affiliations of Roxana Rustomjee include South African Medical Research Council & Medical Research Council.
Papers
More filters
Journal ArticleDOI
Rapid molecular detection of tuberculosis and rifampin resistance.
Catharina Boehme,Pamela Nabeta,Doris Hillemann,Mark P. Nicol,Shubhada Shenai,Fiorella Krapp,Jenny Allen,Rasim Tahirli,Robert Blakemore,Roxana Rustomjee,Ana Milovic,Martin Jones,Sean M. O'Brien,David H. Persing,Sabine Ruesch-Gerdes,Eduardo Gotuzzo,Camilla Rodrigues,David Alland,Mark D. Perkins +18 more
TL;DR: The MTB/RIF test provided sensitive detection of tuberculosis and rifampin resistance directly from untreated sputum in less than 2 hours with minimal hands-on time.
Journal ArticleDOI
The diarylquinoline TMC207 for multidrug-resistant tuberculosis
Andreas H. Diacon,Alexander S. Pym,Martin P. Grobusch,R. F. Patientia,Roxana Rustomjee,Liesl Page-Shipp,Christoffel Pistorius,Rene Krause,Mampedi Bogoshi,Gavin J. Churchyard,Amour Venter,Jenny Allen,Juan Carlos Palomino,Tine De Marez,Rolf van Heeswijk,Nacer Lounis,Paul Meyvisch,Johan Verbeeck,Wim Parys,Karel de Beule,Koen Andries,David F Mc Neeley +21 more
TL;DR: The clinical activity of TMC207 validates ATP synthase as a viable target for the treatment of tuberculosis.
Journal ArticleDOI
A Four-Month Gatifloxacin-Containing Regimen for Treating Tuberculosis
Corinne Merle,Katherine Fielding,Omou Bah Sow,M. Gninafon,Mame B. Lo,Thuli Mthiyane,Joseph Odhiambo,Evans Amukoye,Boubacar Bah,Ferdinand Kassa,Roxana Rustomjee,Bouke C. de Jong,John R. Horton,Christian Perronne,Charalambos Sismanidis,Olivier Lapujade,Piero Olliaro,Christian Lienhardt,Abstr Act +18 more
TL;DR: Noninferiority of the 4-month regimen to the standard regimen with respect to the primary efficacy end point was not shown, and there was no evidence of increased risks of prolongation of the QT interval or dysglycemia with the 4 month regimen.
Journal Article
A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
Roxana Rustomjee,Christian Lienhardt,Thomas P. Kanyok,Geraint Davies,J Levin,Thuli Mthiyane,C. Reddy,A. W Sturm,F. A. Sirgel,Jenny Allen,David Coleman,B Fourie,Denis A. Mitchison,Gatifloxacin for Tb (Oflotub) study team +13 more
TL;DR: GFX and MFX improve the sterilising activity of regimens and might shorten treatment; their progression into Phase III trials therefore seems warranted.
Journal ArticleDOI
Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC207 in Treatment of Pulmonary Tuberculosis
Roxana Rustomjee,Andreas H. Diacon,J. Allen,Venter A,C. Reddy,R. F. Patientia,Thuli Mthiyane,T. De Marez,R. van Heeswijk,R. Kerstens,Anil Koul,K. De Beule,Peter R. Donald,D. F. McNeeley +13 more
TL;DR: In this early bactericidal activity study, 75 patients with smear-positive pulmonary tuberculosis were randomized to once-daily oral TMC207 and the drug was well tolerated, and no study drug-related serious adverse events occurred.